Reneo Pharmaceuticals, Inc. (RPHM) |
|
7.39 -0.26 (-3.4%)
|
09-27 11:26 |
|
Open: |
7.61 |
Pre. Close: |
7.65 |
|
High:
|
7.93 |
Low:
|
7.32 |
|
Volume:
|
62,190 |
Market Cap:
|
250(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 10:49:20 AM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 9.92 One year: 11.59 |
| Support: |
Support1: 6.81 Support2: 5.78 |
| Resistance: |
Resistance1: 8.5 Resistance2: 9.92 |
| Pivot: |
7.28  |
| Moving Average: |
MA(5): 7.56 MA(20): 7.06
MA(100): 7.22  MA(250): 5.24 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 69.1 %D(3): 75.4 |
| RSI: |
RSI(14): 60.3 |
| 52-week: |
High: 11.29 Low: 1.78 |
| Average Vol(K): |
3-Month: 137 (K) 10-Days: 140 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RPHM ] has closed below upper band by 15.3%. Bollinger Bands are 46.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.51 - 8.56 |
8.56 - 8.6 |
|
Low:
|
7.5 - 7.55 |
7.55 - 7.59 |
|
Close:
|
7.58 - 7.66 |
7.66 - 7.73 |
|
Company Description |
|
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California. |
Headline News |
Fri, 22 Sep 2023
Prelude Capital Management LLC Invests $89000 in Reneo ... - MarketBeat
Tue, 29 Aug 2023
Reneo Pharmaceuticals to Participate in Upcoming Investor ... - GlobeNewswire
Thu, 10 Aug 2023
Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) stock price dropped 10% last week; private equity firms would not be happy - Yahoo Finance
Mon, 31 Jul 2023
Should Biotechnology Stock Reneo Pharmaceuticals Inc (RPHM) Be in Your Portfolio Monday? - InvestorsObserver
Mon, 26 Jun 2023
Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices - Yahoo Finance
Mon, 05 Jun 2023
Is Reneo Pharmaceuticals Inc (RPHM) Stock a Good Value Monday? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
34 (M) |
| Shares Float |
15 (M) |
|
% Held by Insiders
|
2 (%) |
|
% Held by Institutions
|
58.9 (%) |
|
Shares Short
|
2,030 (K) |
|
Shares Short P.Month
|
1,470 (K) |
Stock Financials |
|
EPS
|
-2.25 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.92 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-29.2 |
|
Return on Equity (ttm)
|
-47.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.94 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-52 (M) |
|
Levered Free Cash Flow
|
-30 (M) |
Stock Valuations |
|
PE Ratio
|
-3.42 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1.95 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-5.04 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
